AVAI BIO Financials

AVAI

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE March

This page shows AVAI BIO (AVAI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AVAI FY2025 2026-04-22

External financing is keeping the business alive while liquidity tightens, and the balance sheet explains more than reported sales.

A financing inflow of $1.36M almost fully offset operating cash burn of $1.32M, so outside capital was functioning as replacement fuel for the business rather than as balance-sheet repair. Even afterward, cash was only $81K and the current ratio was 0.1x, showing that the raise did little to restore ordinary bill-paying flexibility.

Negative equity deepened to -$1.56M while liabilities stayed near $1.79M, which means losses and cash use were eroding the asset base faster than obligations were being reduced. That leaves the company dependent on continued support from capital providers because existing assets do not cover claims already recorded.

Share count dilution was also heavy, rising from 38.5M to 137.4M while liabilities barely changed, indicating new equity mainly financed survival time rather than materially shrinking the liability burden. In plain terms, ownership expanded far faster than the balance sheet improved.

Financial Health Signals

Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of AVAI BIO's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity

AVAI BIO's current ratio of 0.05 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$1.1M

AVAI BIO's EBITDA was -$1.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Net Income

N/A

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$81K

YoY+28744.5%

5Y CAGR+24.3%

AVAI BIO held $81K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

137M

YoY+17.2%

AVAI BIO had 137M shares outstanding in fiscal year 2025. This represents an increase of 17.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

AVAI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$276K-44.7%	$500K-58.8%	$1.2M+492.9%	$205K
Cost of Revenue	N/A	N/A	$317K-55.4%	$711K-42.3%	$1.2M+166.9%	$461K
Gross Profit	N/A	N/A	-$40K+80.8%	-$211K-1174.8%	-$17K+93.5%	-$256K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	$27K
SG&A Expenses	$762K-46.5%	$1.4M+506.3%	$235K-47.7%	$449K+118.9%	$205K-10.5%	$229K
Operating Income	N/A	N/A	-$349K-375.8%	$127K-58.1%	$302K+334.4%	$70K
Interest Expense	N/A	N/A	$276K-70.0%	$921K-24.1%	$1.2M+69.2%	$717K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	-$349K-175.8%	-$127K+58.1%	-$302K-334.4%	-$70K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$24K	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$190K-28.3%	$265K+23.9%	$214K	N/A	$260K-38.5%	$423K+66.0%	$255K	N/A
Operating Income	-$554K-22.2%	-$453K+7.1%	-$488K	N/A	$452K-27.4%	$623K+217.8%	-$529K	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$554K-22.2%	-$453K+7.1%	-$488K	N/A	-$452K+27.6%	-$625K-18.2%	-$529K	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AVAI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$225K-30.2%	$322K+33.4%	$241K-46.9%	$455K-44.3%	$816K+94.4%	$420K
Current Assets	$93K-19.8%	$116K+7.9%	$108K-67.5%	$331K-46.7%	$620K+318.1%	$148K
Cash & Equivalents	$81K+28744.5%	$281-99.7%	$107K+222.8%	$33K-44.9%	$60K+121.1%	$27K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$4K-94.1%	$64K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.8M0.0%	$1.8M+104.5%	$875K+1.7%	$860K-24.8%	$1.1M+149.9%	$458K
Current Liabilities	$1.8M0.0%	$1.8M+104.5%	$875K+1.7%	$860K-24.8%	$1.1M+149.9%	$458K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.6M-6.6%	-$1.5M-131.6%	-$633K-56.1%	-$406K-23.9%	-$327K-768.8%	-$38K
Retained Earnings	-$4.1M-38.4%	-$3.0M-251.0%	-$848K-271.0%	$496K+34.3%	$369K+650.9%	-$67K

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$173K-25.3%	$231K+59.2%	$145K-35.3%	$225K+28.5%	$175K-3.4%	$181K-26.1%	$245K-23.9%	$322K
Current Assets	$61K-46.1%	$113K+458.1%	$20K-78.3%	$93K+238.6%	$28K+94.6%	$14K-75.8%	$58K-49.6%	$116K
Cash & Equivalents	$50K-45.2%	$92K+814.3%	$10K-87.6%	$81K+2540.2%	$3K+73.3%	$2K+299.1%	$444+58.0%	$281
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.0M+17.2%	$2.5M+18.5%	$2.1M+19.5%	$1.8M-22.6%	$2.3M+15.8%	$2.0M-14.4%	$2.3M+30.2%	$1.8M
Current Liabilities	$3.0M+17.2%	$2.5M+18.5%	$2.1M+19.5%	$1.8M-22.6%	$2.3M+15.8%	$2.0M-14.4%	$2.3M+30.2%	$1.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.8M-21.5%	-$2.3M-15.5%	-$2.0M-27.3%	-$1.6M+26.8%	-$2.1M-17.6%	-$1.8M+12.9%	-$2.1M-42.1%	-$1.5M
Retained Earnings	-$5.6M-10.9%	-$5.1M-9.8%	-$4.6M-11.8%	-$4.1M+10.1%	-$4.6M-11.0%	-$4.1M-17.8%	-$3.5M-17.8%	-$3.0M

AVAI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$1.3M-2328.2%	-$54K-110.2%	$535K+2217.1%	$23K-82.3%	$131K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	-$149K-344.6%	-$34K+0.6%	-$34K-57.8%	-$21K+92.1%	-$271K
Financing Cash Flow	N/A	$1.4M+741.3%	$162K-65.8%	$474K+1263.3%	$35K-79.3%	$168K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$347K+6.6%	-$372K-54.6%	-$240K-28.2%	-$188K-39.6%	-$134K+83.7%	-$826K-6403.3%	-$13K+90.7%	-$137K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Financing Cash Flow	$306K-32.6%	$453K+167.8%	$169K-36.2%	$265K+95.7%	$136K-83.6%	$827K+6331.3%	$13K-90.5%	$136K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AVAI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	-14.6%+27.5pp	-42.2%-40.8pp	-1.4%+123.8pp	-125.2%
Operating Margin	N/A	N/A	-126.3%-151.6pp	25.3%+0.4pp	24.9%-9.1pp	34.0%
Net Margin	N/A	N/A	-126.3%-101.0pp	-25.3%-0.4pp	-24.9%+9.1pp	-34.0%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	-144.5%-116.7pp	-27.8%+9.2pp	-37.0%-20.5pp	-16.6%
Current Ratio	0.05-0.0	0.06-0.1	0.12-0.3	0.38-0.2	0.54+0.2	0.32
Debt-to-Equity	-1.14+0.1	-1.22+0.2	-1.38+0.7	-2.12+1.4	-3.49+8.7	-12.14
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-320.2%-124.4pp	-195.8%+139.8pp	-335.6%	N/A	-258.6%+86.7pp	-345.3%-129.3pp	-215.9%	N/A
Current Ratio	0.02-0.0	0.04+0.0	0.01-0.0	0.05+0.0	0.010.0	0.01-0.0	0.03-0.0	0.06
Debt-to-Equity	-1.06+0.0	-1.10-0.0	-1.07+0.1	-1.14-0.1	-1.08+0.0	-1.10+0.0	-1.12+0.1	-1.22
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.05), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Ntg Clarity Ntwk NYWKF

$28.8M

Minehub Technolo MHUBF

$52.9M

Argo Corp ARGHF

$64.9M

Cloopen Group Holding Limited RAASY

$125.5M

Xtract One Technologies Inc. XTRAF

$91.0M

Frequently Asked Questions

What is AVAI BIO's EBITDA?

AVAI BIO (AVAI) had EBITDA of -$1.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What are AVAI BIO's total assets?

AVAI BIO (AVAI) had $225K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does AVAI BIO have outstanding?

AVAI BIO (AVAI) had 137M shares outstanding as of fiscal year 2025.

What is AVAI BIO's current ratio?

AVAI BIO (AVAI) had a current ratio of 0.05 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is AVAI BIO's debt-to-equity ratio?

AVAI BIO (AVAI) had a debt-to-equity ratio of -1.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is AVAI BIO's debt-to-equity ratio negative or unusual?

AVAI BIO (AVAI) has negative shareholder equity of -$1.6M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is AVAI BIO?

AVAI BIO (AVAI) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.